Can analysts adopt a bullish outlook for Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)?

Investors sentiment decreased to 0.94 in 2018 Q3. Its down 0.30, from 1.24 in 2018Q2. It is negative, as 9 investors sold Intra-Cellular Therapies, Inc. shares while 39 reduced holdings. 11 funds opened positions while 34 raised stakes. 36.60 million shares or 0.99% less from 36.97 million shares in 2018Q2 were reported.
Crow Point Partners Ltd Liability Corp stated it has 11,499 shares. Alpine Woods Ltd Liability Corporation stated it has 20,800 shares or 0.09% of all its holdings. 258,295 were accumulated by Schwab Charles Mgmt. Manufacturers Life Ins The has invested 0% of its portfolio in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). Goldman Sachs has invested 0% of its portfolio in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). National Bank Of New York Mellon invested in 207,544 shares or 0% of the stock. Millennium Mngmt Limited Liability Corp holds 0.01% or 543,997 shares in its portfolio. Keybank National Association Oh stated it has 13,378 shares or 0% of all its holdings. Credit Suisse Ag has 21,877 shares for 0% of their portfolio. D E Shaw & holds 0.01% of its portfolio in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) for 194,813 shares. Ubs Asset Mgmt Americas holds 0% or 14,700 shares. 52,516 are held by Macquarie Group Limited. Group One Trading L P holds 53,541 shares or 0.01% of its portfolio. Jacobs Levy Equity Mngmt Inc invested in 10,625 shares or 0% of the stock. Price T Rowe Assoc Incorporated Md, a Maryland-based fund reported 441,178 shares.

Since November 9, 2018, it had 0 insider buys, and 7 sales for $1.99 million activity. Halstead Michael had sold 24,566 shares worth $284,418 on Friday, January 4. The insider Davis Robert E sold $109,630. Hineline Lawrence J. also sold $284,383 worth of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) shares. Vanover Kimberly E. also sold $116,979 worth of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) shares. Mates Sharon sold $604,310 worth of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) on Friday, January 4.

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Ratings Coverage

Among 2 analysts covering Intra-Cellular Therapies (NASDAQ:ITCI), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Intra-Cellular Therapies had 2 analyst reports since August 23, 2018 according to SRatingsIntel. Below is a list of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) latest ratings and price target changes.

13/11/2018 Broker: Leerink Swann Rating: Outperform New Target: $27 Initiates Coverage On
23/08/2018 Broker: Cantor Fitzgerald Rating: Overweight New Target: $32 Initiates Coverage On

The stock decreased 3.01% or $0.4 during the last trading session, reaching $12.87. About 59,430 shares traded. Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) has risen 1.66% since January 14, 2018 and is uptrending. It has outperformed by 1.66% the S&P500.

Intra-Cellular Therapies, Inc., a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including ParkinsonÂ’s and AlzheimerÂ’s disease. The company has market cap of $704.33 million. The firm is developing its lead drug candidate, lumateperone, known as ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, depression, and other neuropsychiatric and neurological disorders. It currently has negative earnings. Lumateperone, a molecule, is in Phase III clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer's disease.

Another recent and important Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) news was published by which published an article titled: “Intra-Cellular Therapies (ITCI) Announces ITI-007 Phase 3 Missed Primary Endpoint in Schizophrenia –” on September 28, 2016.

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Institutional Positions Chart

(adsbygoogle = window.adsbygoogle || []).push({});

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.